Mallinkcrodt, a UK-based manufacturer of speciality drugs and medical equipment, has acquired US immunotherapy treatment group Therakos for $1.33 billion.
The perimeters of the deal, through American private equity firm Gores Group, allow Mallincrkrodt complete access to Therkos’ specialised cell therapy platform, designed for patients who aren’t responded to any other forms of treatment. It was approved for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL). This deal follows the company’s $2.3 billion acquisition of Ikaria in March.
The move offers further room for expansion across hospitals, with multimodal surgical pain management and critical care respiratory therapies in neonatal intensive care units. This will also include new therapies that incorporate, utilise and encourage the patient’s own immune system to fight disease.
Mark Trudeau, Mallinckrodt Chief Executive, comments: “Therakos is, quite simply, another excellent fit for Mallinckrodt. [It] demonstrates our ongoing commitment to building a strong, highly profitable hospital growth business as we build and diversity [the] Speciality Brands portfolio.”
The deal is expected to close in the third quarter of 2015.